Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: A single institution experience

Gynecologic Oncology

Volumn 123, Issue 1, 2011, Pages 37-42

  Bamias, A ^a   Karadimou, A ^a   Soupos, N ^a   Sotiropoulou, M ^b   Zagouri, F ^a   Haidopoulos, D ^a   Thomakos, N ^a   Rodolakis, A ^a   Antsaklis, A ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

Early stage; Ovarian cancer; Prognostic factors; Serous; Tumor type

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PACLITAXEL; PROGNOSIS;

EID: 80052578547     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.06.033     Document Type: Article

References (31)

1. I.B. Vergote, L.N. Vergote-De Vos, V.M. Abeler, M. Aas, M.W. Lindegaard, K.E. Kjorstand, and C.G. Trope Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer Cancer 69 1992 741 749
2. F.Y. Ahmed, E. Wiltshaw, R.P. A'Hern, N.J. Shepherd, P. Blake, C. Fisher, and M.E. Gore Natural history and prognosis of untreated stage I epithelial ovarian carcinoma J Clin Oncol 14 1996 2968 2975 (Pubitemid 26371455)
3. J. Brugghe, J.P.A. Baak, E. Wiltshaw, M. Brikhuis, G.A. Meijer, and C. Fisher Quantitative prognostic features in FIGO I ovarian cancer patients without postoperative treatment Gynecol Oncol 68 1998 47 53 (Pubitemid 28109823)
4. J.B. Trimbos, I. Vergote, G. Bolis, J.B. Vermorken, C. Mangioni, and C. Madronal Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial J Natl Cancer Inst 95 2003 113 125 (Pubitemid 36193260)
5. N. Colombo, D. Guthrie, S. Chiari, M. Parmar, W. Qian, and A.M. Swart International collaborative ovarian neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer J Natl Cancer Inst 95 2003 125 132 (Pubitemid 36193261)
6. J.B. Trimbos, M. Parmar, I. Vergote, D. Guthrie, G. Bolis, and N. Colombo International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma J Natl Cancer Inst 95 2003 105 112 (Pubitemid 36196730)
7. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Engl J Med 334 1996 1 6 (Pubitemid 26012496)
8. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J Natl Cancer Inst 92 2000 699 708 (Pubitemid 30365530)
9. R.F. Ozols, B.N. Bundy, B. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J Clin Oncol 21 2003 3194 3200 (Pubitemid 46606249)
10. J. Bell, M.F. Brady, R.C. Young, J. Lage, J.L. Walker, K.Y. Look, C.S. Rose, and N.M. Spirtos Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a gynaecologic oncology group study Gynecol Oncol 102 2006 432 439 (Pubitemid 44353663)
11. I. Vergote, J. De Brabander, A. Fyles, K. Bertelsen, N. Einhorn, and P. Sevelda Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma Lancet 357 2001 176 182 (Pubitemid 32108089)
12. R.C. Young, L.A. Walton, S.S. Ellenberg, H.D. Homesley, G.D. Wilbanks, and D.G. Decker Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials N Engl J Med 322 1990 1021 1027 (Pubitemid 20146659)
13. J.K. Chan, C. Tian, B.J. Monk, T. Herzog, D.S. Kapp, J. Bell, and R.C. Young Prognostic factors for high-risk early-stage epithelial ovarian cancer Cancer 112 2008 2202 2210
14. A. Bamias, C. Papadimitriou, E. Efstathiou, A. Rodolakis, G. Vlahos, and Z. Voulgaris Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group BMC Cancer 6 2006 228
15. R.J. Kurman, and I.M. Shih The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory Am J Surg Pathol 34 2010 433 443
16. G. Zanetta, S. Rota, S. Chiari, C. Bonazzi, G. Bratina, V. Torri, and C. Mangioni The accuracy of staging: an important prognostic determination in stage I ovarian carcinoma Ann Oncol 9 1998 1097 1101 (Pubitemid 28518148)
17. 32P) Ann Oncol 6 1995 887 893
18. A. Bamias, T. Psaltopoulou, M. Sotiropoulou, D. Haidopoulos, E. Lianos, and E. Bournakis Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy Cancer 116 2010 1462 1468
19. W.E. Winter III, G.L. Maxwell, C. Tian, J.W. Carlson, R.F. Ozols, and P.G. Rose J Clin Oncol 25 2007 3621 3627
20. J.D. Seidman, A.V. Yelemanova, F. Khedmati, M.A. Bidus, L. Dainty, C.R. Boice, and J.A. Cosin Prognostic factors for stage I ovarian carcinoma Int J Gynecol Pathol 29 2010 1 7
21. M. Kobel, S.E. Kalloger, J.L. Santos, D.G. Huntsman, C.B. Gilks, and K.D. Swenerton Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications Gynecol Oncol 116 2010 50 56
22. T. Lee, G.V. Krepart, and R.J. Lotocki Clinically apparent early stage invasive ovarian epithelial carcinoma: should all be treated similarly? Gynecol Oncol 74 1999 252 254 (Pubitemid 29377221)
23. C.B. Gilks, D. Ionescu, S.E. Kalloger, M. Kobel, J. Irving, J. Irving, and Clarke Tumor cell type can reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma Hum Pathol 39 2008 1239 1251
24. R.A. Soslow Histologic subtypes of ovarian carcinoma: an overview Int J Gynecol Pathol 27 2008 161 174 (Pubitemid 351450675)
25. S.G. Silveberg Histopathological grading of ovarian carcinoma: a review and proposal Int J Gynecol Pathol 19 2000 7 15
26. S. Kommoss, D. Schmidt, F. Kommoss, J. Heindrich, P. Harter, and J. Pfisterer Histological grading in a large series of advanced stage ovarian carcinomas by three widely used grading systems: consistent lack of prognostic significance. A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol) Vircjows Arch 454 2009 249 256
27. M. Markman An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer Cancer J 15 2009 105 109
28. R.A. Burger, M.F. Brady, M.A. Bookman, J.L. Walker, H.D. Homesley, and J. Fowler Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study J Clin Oncol 28 Suppl 15 2010 5s
29. T. Perren, A.M. Swart, J. Pfisterer, J. Ledermann, A. Lortholary, and G. Kristensen ICON7: a phase III randomized Gynaecologic Cancer Intergroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC) 35th ESMO Congress 2010 LBA4
30. L.N. Abaid, B.H. Goldstein, J.P. Micha, M.A. Rettenmaier, J.V. Brown III, and M. Markman Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma Oncology 78 2010 389 393
31. J.K. Chan, C. Tian, G.F. Fleming, B.J. Monk, T.J. Herzog, D.S. Kapp, and J. Bell The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study Gynecol Oncol 116 2010 301 306